Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents

NCT07301541 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2027-01
Last updated
2026-04-13

Condition(s) studied

Binge Eating DisorderBinge EatingLoss of Control EatingOverweight , ObesityChildrenChildhood ObesityScreeningBED

Investigational drug(s) / intervention(s)

A 10-week multicomponent camp intervention for childrenA BED intervention for parents

A 10-week multicomponent camp intervention for children: A 10-week multicomponent camp intervention for participating children only, focusing on social and physical activities, healthy meals, and daily physical activities.

A BED intervention for parents: An add-on virtual parent-based intervention providing knowledge about BED and tools to support their child's eating after the multicomponent camp intervention.

Study summary

The main purpose is to investigate the effectiveness of a 10-week multicomponent camp intervention to reduce BE behavior in children and adolescents and explore in a randomized controlled setting if a parent-based BED-intervention has any add-on effect, attenuating the development of BE behavior in this sample. The study will include an initial follow-up assessment scheduled 10-12 weeks after camp completion and plans for long-term follow-up assessments one, three and five years after inclusion.

Overall, we hypothesize that the multicomponent camp intervention will effectively reduce BE behavior in children and adolescents. Furthermore, we hypothesize that participants whose parents are randomized to receive the parental BED intervention will show a lower prevalence of BE behavior one year after the camp intervention compared with children whose parents receive standard care.

Eligibility

Sex
ALL
Min age
7 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Attending the camp in Hobro or Fjordmark from January 2027 to December 2027 * 7-14 years of age at recruitment * Participants must have written informed consent from parent/guardian before camp to participate * At least one parent/guardian submit written informed consent to participate in the study with their child Exclusion Criteria: * A medical condition affecting dietary intake and/or eating behavior * Taking weight loss medication * The parent/guardian don't understand the written informed consent * Participant or parent/guardian are unwilling to or unable to comply with the study protocol and instructions given by the study staff.

Primary outcome measure(s)

  • Changes in Binge eating behavior using the STOB-screening tool — Baseline, 10-weeks (post-intervention), 10-12 weeks after the intervention, and 1, 3 and 5 years after the intervention.
    The STOB-screening tool consist of five yes/no questions + one question about number of overeating episodes
  • Changes in prevalence of Binge eating disorder (BED) using the ChEDE — Baseline, and 10-weeks (post-intervention).
    Binge eating disorder will be assessed using the Child Eating Disorder Examination interview

Trial sites (2)

FacilityCityRegionStatus
Julemærkehjemmet Hobro Hobro Denmark
Julemærkehjemmet Fjordmark Kruså Denmark
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07301541 on ClinicalTrials.gov ↗ ← All trials in Denmark